Take a detailed look at the record of completed trials over the calendar year, highlighting key trends by therapeutic area; the company sponsorship landscape; and trial phase, including progress of designated pivotal trials and success in meeting endpoints. Trialtrove’s awaited annual review of clinical trials initiated by industry sponsors is a useful gauge of the diversity and innovative potential of biopharma’s investments in R&D. This year’s report reveals that, while there is evidence of consistency in many aspects of the clinical trial landscape, changes are in the wind – particularly as companies outside the pharma top 20 now contribute more completed trials than any other type of sponsor. Find out the trends that remained constant and the trial upsets that marked 2018.